Tag Archive for: Antibiotic resistance

Last year GSK made a strategic move to focus solely on biopharma, and it is already realizing the benefits of a more targeted business.

Data from the Phase III REVISIT and ASSEMBLE studies showed that Pfizer’s investigational antibiotic combination aztreonam-avibactam could safely cure infections caused by Gram-negative bacteria, the company announced Thursday.

This exclusive licence agreement gives GSK rights to commercialize Brexafemme for vulvovaginal candidiasis and recurrent VVC while continuing to develop ibrexafungerp, which is in phase III clinical trials for the potential treatment of invasive candidiasis (IC), a life-threatening fungal infection.

Antibiotics maker Melinta Therapeutics, which has commercialization rights for the drug in the U.S. market, plans to make rezafungin available this summer.

Potentially deadly fungal infections with Candida auris are spreading rapidly in U.S. healthcare facilities, with cases nearly doubling between 2020 and 2021, the Centers for Disease Control and Prevention said.

Increased drug resistance in bacteria causing bloodstream infections, including against last-resort antibiotics, was seen in the first year of the coronavirus pandemic, a World Health Organization report based on data from 87 countries in 2020 showed.

Infections from some antibiotic-resistant pathogens known as superbugs have more than doubled in health care facilities in Europe, an EU agency said on Thursday, providing further evidence of the wider impact of the COVID-19 pandemic.

Sandoz, the generic drugs business that will be spun off its parent Novartis, will boost investment in its European antibiotics production network by 50 million euros ($50 million) on strong global demand for bacteria-fighting medicines.

In a first, Prolacta Bioscience recently published a proof of concept study showing that components of human breast milk can treat the adult microbiome without antibiotics.

U.S. deaths from bacteria resistant to antibiotics, also known as ‘superbugs’, jumped 15% in 2020 as the drugs were widely dispensed to treat COVID-19 and fight off bacterial infections during long hospitalizations, enabling the bugs to evolve, a U.S. government report said on Tuesday.